SPOTLIGHT: L'Oreal selling off chunk of Sanofi stock


L'Oreal is cutting its stake in Sanofi-Aventis by 1.8 percent by selling off shares through sales to institutional investors; the company will retain am 8.7 percent share in the drug maker. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.